Tezosentan
|  | |
|  | |
| Clinical data | |
|---|---|
| ATC code | none | 
| Identifiers | |
| 
 | |
| CAS Number | 180384-57-0  | 
| PubChem (CID) | 151174 | 
| ChemSpider | 133242  | 
| UNII | 64J9J55263  | 
| ChEMBL | CHEMBL61780  | 
| Chemical and physical data | |
| Formula | C27H27N9O6S | 
| Molar mass | 605.624 | 
| 3D model (Jmol) | Interactive image | 
| 
 | |
| 
 | |
| (verify) | |
Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]
References
- ↑  Urbanowicz, W; Sogni, P; Moreau, R; Tazi, K A; Barriere, E; Poirel, O; Martin, A; Guimont, M C; Cazals-Hatem, D; Lebrec, D (2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. BMJ Publishing Group Ltd & British Society of Gastroenterology. 53 (12): 1844–1849. doi:10.1136/gut.2003.036517. PMC 1774327 . PMID 15542526. . PMID 15542526.
- ↑ "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.